We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some juris ...

Core Viewpoint - The Schall Law Firm is investigating potential securities law violations by Insmed Incorporated following the announcement of disappointing clinical trial results for its drug brensocatib, which led to a significant drop in the company's stock price [1][2]. Group 1: Investigation Details - The investigation is centered on whether Insmed made false or misleading statements or failed to disclose important information to investors [2]. - Insmed's Phase 2b BiRCh study for brensocatib in chronic rhinosinusitis without nasal polyps did not meet its primary or secondary efficacy endpoints, resulting in the decision to discontinue the drug's development [2]. Group 2: Market Reaction - Following the announcement of the trial results, Insmed's shares experienced a decline of nearly 16.1% the next day [2].

Core Viewpoint - The Schall Law Firm is investigating Anavex Life Sciences Corp for potential violations of securities laws following a significant drop in share price after a negative trend vote on its Marketing Authorisation Application for blarcamesine [1] Group 1: Investigation Details - The investigation focuses on whether Anavex issued false or misleading statements or failed to disclose important information to investors [1] - Anavex announced on November 14, 2025, that it received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) regarding its Marketing Authorisation Application for blarcamesine [1] Group 2: Market Reaction - Following the announcement of the negative trend vote, shares of Anavex fell by more than 35.9% on the same day [1]

Core Viewpoint - The Schall Law Firm is investigating claims against Alaska Air Group, Inc. for potential violations of securities laws related to misleading statements and undisclosed information impacting investors [1] Group 1: Investigation Details - The investigation focuses on whether Alaska Air issued false or misleading statements or failed to disclose relevant information to investors [1] - On October 23, 2025, Alaska Air announced an IT outage that caused a systemwide ground stop for Alaska and Horizon Air flights, leading to significant delays and cancellations [1] Group 2: Market Reaction - Following the announcement of the IT outage, shares of Alaska Air fell by more than 6.1% the next day [1]

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into potential breaches of fiduciary duties by the board members of Sealed Air Corporation regarding the proposed acquisition by CD&R, which is perceived to undervalue the company’s shares [1][2]. Group 1: Company Overview - Sealed Air Corporation has entered into a definitive merger agreement with CD&R, where CD&R will acquire all outstanding shares of Sealed Air common stock for $42.15 per share in cash [2]. Group 2: Legal Firm Background - Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with multiple offices across the United States, representing both individual and institutional investors in securities class action lawsuits [3]. Group 3: Achievements of the Law Firm - In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, having recovered approximately $90.725 million for clients in cases where it served as lead or co-lead counsel [4].

Core Viewpoint - The Schall Law Firm is investigating Exelixis, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Exelixis issued false or misleading statements and failed to disclose critical information to investors [2]. - Exelixis reported Q2 2025 financial results on July 28, 2025, indicating product revenue for cabozantinib was below expectations [2]. - The company decided not to proceed to the phase 3 portion of the STELLAR-305 study due to emerging competition and assessment of other commercial opportunities [2]. Group 2: Market Reaction - Following the announcement regarding the phase 3 trial decision, Exelixis shares fell by almost 16.8% the next day [2].

Core Viewpoint - The Schall Law Firm is investigating Lantheus Holdings, Inc. for potential violations of securities laws following disappointing Q2 2025 earnings results and a significant drop in share price [1][2]. Group 1: Investigation Details - The investigation centers on whether Lantheus made false or misleading statements and failed to disclose important information to investors [2]. - Following the announcement of Q2 2025 earnings on August 6, 2025, Lantheus reported revenue and earnings per share that fell short of expectations, leading to a nearly 28.6% decline in share price on the same day [2]. Group 2: Financial Performance - Lantheus lowered its guidance for full year revenue and diluted earnings per share, indicating a negative outlook for the company's financial performance [2].

Core Viewpoint - The Schall Law Firm is investigating Coty Inc. for potential violations of securities laws following disappointing financial results for Q4 and FY 2025, which led to a significant drop in share price [1][2]. Financial Performance - Coty reported Q4 and FY 2025 financial results on August 20, 2025, which disappointed the market [2]. - The company attributed its poor performance to delays in identifying weaknesses in U.S. execution, retailer inventory buildup, and challenges from previous fiscal year innovations [2]. - A decline in the cosmetics sector was noted, driven by value-seeking behavior, fatigue with innovation, and U.S.-specific factors such as in-store and anti-theft measures and immigration policy changes [2]. - Following the announcement, Coty's shares fell by more than 21% the next day [2].

Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the directors and management of Olo Inc. in relation to its acquisition by Thoma Bravo for $10.25 per share [1]. Group 1 - The investigation by the Schall Law Firm focuses on whether the Olo board acted in the best interests of its shareholders during the acquisition process [1]. - Olo Inc. has agreed to be acquired by Thoma Bravo at a price of $10.25 per share [1].

Group 1 - The Schall Law Firm is investigating claims on behalf of investors of Simulations Plus, Inc. for potential violations of securities laws [1] - The investigation centers on whether Simulations Plus issued false or misleading statements and failed to disclose relevant information to investors [2] - Following the Q3 2025 earnings report, Simulations Plus reported sales of $20.4 million, which was below the consensus estimate of $20.9 million, leading to a decline in the company's shares [2] Group 2 - The preliminary third-quarter sales figures released in June indicated lower expectations at $19 million to $20 million, compared to a consensus of $22.78 million [2]